论文部分内容阅读
近日,FDA批准新型抗病毒药物dolutegravir(Tivicay)治疗1型人免疫缺陷病毒(HIV-1)感染。dolutegravir是一种整合酶链转移抑制剂,可干扰HIV繁殖所需相关酶,应与其他抗病毒药物联合治疗。本品为丸剂,一日1次服用。适用人群包括HIV感染初治或经治(既往接受过其他整合酶链转移抑制剂治疗)的成年患者,以及包括12岁及以上、体重至少40 kg的初治或经治(但既往未接受过其他整合酶链转移抑制剂治疗)的儿童HIV感染者。本品的安全性和有效性基于四项共纳入2 539例受试者的临床研究。受试者随机接受本品或雷特格韦(raltegravir),均分别联用其他抗病毒药
Recently, the FDA approved the new antiviral drug dolutegravir (Tivicay) for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. Dolutegravir is an integrase inhibitor of enzyme transfer that interferes with the enzymes required for HIV multiplication and should be combined with other antiviral drugs. This product is a pill, taken once a day. The population of interest includes adult patients who have undergone treatment of HIV infection or who have undergone previous treatment with other integrase inhibitors as well as those who have undergone treatment or treatment of at least 40 kg of body weight at least 12 years and older who have not previously received Other Integrative Enzyme Chain Transfer Inhibitors) in Children with HIV Infection. The safety and efficacy of this product is based on a clinical study involving a total of 2 539 subjects on a quadruplicate basis. Subjects were randomized to either receive this product or raltegravir, both in combination with other antiviral agents